Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pemvidutide by Altimmune for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Pemvidutide is under clinical development by Altimmune and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Altimmune's Pemvidutide?
Pemvidutide is a synthetic peptide commercialized by Altimmune, with a leading Phase II program in Obesity. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of Altimmune's Pemvidutide?
Pemvidutide is a synthetic peptide commercialized by Altimmune, with a leading Phase II program in Obesity. According to Globaldata, it...